StreetAlpha
13F holdings · Q3 2026

Vivo Capital

Palo Alto, CA · files as Vivo Capital, LLC
Know the moment Vivo Capital filesYou follow Vivo Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 1674712

Vivo Capital reported 50 stocks worth $909M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PRAX (8.7%), TRVI (6.7%) and ERAS (6.5%). Compared with Q2 2026, the fund opened new positions in ENTX, KRSA and BLSM, added to AVBP, ANRO and FTH, trimmed TRVI, ERAS and SABS and sold out of SVA, DNTH and GERN.

Latest filing: what Vivo Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
8 new5 added8 trimmed5 sold outBought about $136M · sold about $149M
New 8
See all 8 →
Added 5
Trimmed 8
See all 8 →
Sold out 5

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$909M−17.0% vs last quarter
Stocks held508 new · 5 sold out
Top 5 weight32.3%spread out
Turnover31%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PRAX
Praxis Precision Medicines I
$79M8.7%271KNo change6 of 8
2
TRVI
Trevi Therapeutics Inc
$60.6M6.7%4.2M−865K (−17%)8 of 8
3
ERAS
Erasca Inc
$58.9M6.5%4M−107K (−3%)8 of 8
4
AVBP
Arrivent Biopharma Inc
$54.1M6.0%1.8M+105K (+6%)3 of 8
5
ABVX
Abivax SA
$41.1M4.5%415KNo change5 of 8
6
ENTX
Entera Bio Ltd
$35.7M3.9%12.3MNew position1 of 8
7
ACRS
Aclaris Therapeutics Inc
$35.2M3.9%6.7MNo change8 of 8
8
ANRO
Alto Neuroscience Inc
$34.7M3.8%1.4M+151K (+12%)4 of 8
9
TNGX
Tango Therapeutics Inc
$34.4M3.8%1.4MNo change6 of 8
10
CRVS
Corvus Pharmaceuticals Inc
$32.3M3.6%2.8MNo change8 of 8
🔒 40 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
SVA
Sinovac Biotech Ltd
$38.2M5.9M
DNTH
Dianthus Therapeutics Inc
$34.5M354K
GERN
Geron Corp
$11.1M8.7M
ALXO
Alx Oncology Hldgs Inc
$6.6M3.2M
UNCY
Unicycive Therapeutics Inc
$2.6M550K

Reported value

last 8 quarters
$893MQ4 '24
$755MQ1 '25
$977MQ2 '25
$1.2BQ3 '25
$1.5BQ4 '25
$1.2BQ1 '26
$1.1BQ2 '26
$909MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Vivo Capital 13F FAQ

What does Vivo Capital own?

Vivo Capital reported 50 stocks worth $909M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PRAX (8.7%), TRVI (6.7%) and ERAS (6.5%). The table above lists every position in the filing (the top 10 without an account).

What did Vivo Capital buy and sell in Q3 2026?

Compared with Q2 2026: 8 new positions, 5 added to, 8 trimmed and 5 sold out. New positions include ENTX, KRSA and BLSM. It sold all of SVA, DNTH and GERN.

When will Vivo Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Vivo Capital's portfolio worth?

The Q3 2026 filing reports $909M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.